In reaction to disappointing earnings/guidance:
- AIRG -6.9%, KMX -4.8%, GIS -1.1%
- MSTX -81.3% ( reports top-line results from Phase 3 study in sickle cell disease; study did not meet its primary efficacy endpoint; will hold a conference call tomorrow)
- MIRN -23.6% (to close the ongoing Phase 1 study of MRX34, its investigational microRNA therapy for multiple cancers )
- CDNA -7.2% (announces a proposed offering of common stock)
- AERI -4.7% (cautious mention from biotech blogger Adam Feuerstein)
- PLM -2.4% ( to offer 13,333,333 Units at $0.75/Unit for gross proceeds of $10 mln in a private transaction)
- JKS -2.1% (still checking)
- NFLX -1.5% (presented at GS conf after mkt close yesterday)
- LEI -1.4% (ticking lower; files for 13,009,664 share common stock offering pursuant to the asset purchase agreement by selling stockholders)
- SKX -3.8% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- AAL -1.1% (downgraded to Mkt Perform from Outperform at Raymond James)
- POST -0.9% (downgraded to Mkt Perform from Outperform at BMO Capital )
- DO -0.7% (downgraded to Sell from Neutral at Goldman)
In reaction to strong earnings/guidance:
- ADBE +4.9%, CPRT +4.1%, FDX +3.8%, NUS +1.9%, ( reaches resolution with the SEC, which fully resolves the previously disclosed SEC investigation in its entirety; sees Q3 revs at high end or above prior guidance), GTN+0.6%, DEO +0.5%, (issues trading update ahead of its AGM)
- ABB +0.7% (to sell its Cable Business to NKT Cables for EUR836 mln)
- SPWR +0.5% (8point3 Energy Partners LP to acquire Sunpower's 49% stake in its 102-MW Henrietta Solar Project for about $134 mln)
Select metals/mining stocks trading higher: AU +4.6%, DRD +4.6%, VALE +3.7%, AG +3.5%, GFI +2.9%, GDX+2.5%, ABX +2.3%
Select oil/gas related names showing strength: CHK +3.4%, OAS +2.5%, MRO +2.4%, SSL +2.2%, RIG +1.9%,RDS.A +1.3%, BP +1.2%
Other news:
- EBIO +12.8% (announces deal to acquire privately-held Viventia )
- USEG +10.1% (thinly traded, entered into an Earnings & Participation Agreement on a previously announced project with IronHorse Resources)
- ADMS +9.7% (announces results of EASE LID 3, says the improvement in LID was statistically significant and confirmed safety and efficacy data from earlier pivotal trials),
- CLVS +9.1% (continued strength following today's M&A chatter)
- SPSC +4.9% (to join S&P SmallCap 600)
- FOXF +4.9% (light volume - to join S&P SmallCap 600)
- FATE +4.7% (granted orphan designation by the FDA for ProTmune )
- EXEL +4.3% (will provide update on CABOzantinib in clinical data oral presentation at the ESMO Congress on Oct 10)
- SRPT +3.2% (announces favorable USPTO decisions in Exon 51 and Exon 53 composition of matter patent interference cases against BioMarin Pharmaceutical)
- AGTC +2.4% (CFO disclosed purchase of 10000 shares, worth total of $87.5K )
- KITE +1.6% ( enters an exclusive, worldwide license with the NIH for intellectual property related to multiple T-cell receptor based product candidates for the treatment of tumors expressing mutated KRAS antigens)
- AXAS +1.3% (sells its Portilla field and associated surface acreage for net proceeds of approximately $13 million and its 12,178 acre surface ranch and ½ of the Company's minerals on the property for gross proceeds of $6.7 million)
- TGT +1.3% (announces new $5 billion share repurchase program)
- MSFT +1.1% (dividend increased 8 percent; $40 billion authorized for share repurchase)
- COO +1.1% (to join the S&P 500)
- UPS +1% (following FDX earnings)
- CONN +7.3% (upgraded to Buy from Hold at Stifel)
- ANFI +6.5% (initiated with a Buy at Jefferies)
- ESV +5.7% (upgraded to Buy from Neutral at Goldman )
- PBYI +4.1% (upgraded to Buy at Stifel)
- BCS +3.9% (upgraded to Buy from Hold at HSBC)
- SYRG +2.6% (initiated with a Outperform at Credit Suisse)
- NE +2.5% (upgraded to Neutral from Sell at Goldman)
Gapping down: MSTX -82.2%, MIRN -26.8%, AERI -5.1%, CDNA -3.5%, SKX -3.2%, JKS -1.9%, LEI -1.4%, AIRG-1.1%, COMM -0.9%
SPECIAL SITUATION: MEDIASET (MS: IM) in light of the Vivendi deal dispute - risk/reward skewed to the upside
In this note we present four potential scenarios for Mediaset and their valuation implication given the uncertain situation with Vivendi regarding the sale of Mediaset Premium (“Premium”).
On April 2016 Vivendi offered to acquire 100% of Premium but in July pulled back from its original offer and asked to renegotiate. Vivendi proposed a revised offer of which Mediaset rejected and filed for damages in Italian courts. At the same time there have been rumors in the French press that the two parties are trying to reach a new deal/settlement.
In the report attached we draw four potential scenarios for Mediaset, in order to assess valuation implications of a range of potential alternatives and what could be the upside/downside of each. We believe the market is now pricing a low probability of a future deal and has significantly marked down the valuation of Mediaset Premium. We note that any other outcome and especially an announcement of a revised deal (or even just renewed talks between the parties) could unlock upside in Mediaset shares. We see the downside risk mainly if Premium losses are higher than market expectations and at the same time Vivendi completely abandons the idea of the acquisition.
Below we present a summary of the 4 scenarios and the implied weighted average PT:
Given the attractive risk/reward ratio we would start to build a position of Long MS: IM /Short Mediaset Espana TL5: SM (pro rata of the capital structure) + hedge the rest with short Vivendi.
Full report and analysis attached!